CO5261516A1 - Compuestos de n-(i-feniletil)-5-femil-imidazol-2-amina y composicion que los comprende - Google Patents

Compuestos de n-(i-feniletil)-5-femil-imidazol-2-amina y composicion que los comprende

Info

Publication number
CO5261516A1
CO5261516A1 CO00095863A CO00095863A CO5261516A1 CO 5261516 A1 CO5261516 A1 CO 5261516A1 CO 00095863 A CO00095863 A CO 00095863A CO 00095863 A CO00095863 A CO 00095863A CO 5261516 A1 CO5261516 A1 CO 5261516A1
Authority
CO
Colombia
Prior art keywords
aryl
alkyl
heterocycle
hydrogen
group
Prior art date
Application number
CO00095863A
Other languages
English (en)
Spanish (es)
Inventor
Liu Song
Benjamin Eric Blass
David Edward Portlock
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5261516A1 publication Critical patent/CO5261516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
CO00095863A 1999-12-17 2000-12-18 Compuestos de n-(i-feniletil)-5-femil-imidazol-2-amina y composicion que los comprende CO5261516A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17270999P 1999-12-17 1999-12-17
US19281100P 2000-03-29 2000-03-29

Publications (1)

Publication Number Publication Date
CO5261516A1 true CO5261516A1 (es) 2003-03-31

Family

ID=26868376

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00095863A CO5261516A1 (es) 1999-12-17 2000-12-18 Compuestos de n-(i-feniletil)-5-femil-imidazol-2-amina y composicion que los comprende

Country Status (16)

Country Link
EP (1) EP1237876A1 (zh)
JP (1) JP2003516972A (zh)
KR (1) KR20020062339A (zh)
CN (1) CN1411449A (zh)
AU (1) AU2096901A (zh)
BR (1) BR0016463A (zh)
CA (1) CA2394570A1 (zh)
CO (1) CO5261516A1 (zh)
CZ (1) CZ20021834A3 (zh)
HU (1) HUP0204144A3 (zh)
IL (1) IL149749A0 (zh)
MX (1) MXPA02005957A (zh)
NO (1) NO20022844L (zh)
PE (1) PE20010928A1 (zh)
PL (1) PL356172A1 (zh)
WO (1) WO2001044203A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2367661C2 (ru) 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459763A (en) * 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
JPS54112864A (en) * 1978-02-22 1979-09-04 Teijin Ltd Novel imidazole derivative, its mineral acid salt, and their preparation
DD135724A1 (de) * 1978-04-14 1979-05-23 Annemarie Hetzheim Verfahren zur herstellung von 2-amino-3-phenacyl-benzoxazoliumhalogeniden und 2-amino-1-o-hydroxyphenyl-4-aryl-imidazolen
US4348404A (en) * 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
JPH0753716B2 (ja) * 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
MXPA01011860A (es) * 1999-05-19 2002-05-06 Procter & Gamble Compuestos heterociclicos que contienen imidazo, sus composiciones y usos.

Also Published As

Publication number Publication date
PE20010928A1 (es) 2001-09-12
WO2001044203A1 (en) 2001-06-21
KR20020062339A (ko) 2002-07-25
CN1411449A (zh) 2003-04-16
CZ20021834A3 (cs) 2002-10-16
JP2003516972A (ja) 2003-05-20
MXPA02005957A (es) 2002-10-23
BR0016463A (pt) 2002-08-27
HUP0204144A3 (en) 2003-07-28
NO20022844D0 (no) 2002-06-14
IL149749A0 (en) 2002-11-10
HUP0204144A2 (en) 2003-05-28
NO20022844L (no) 2002-08-19
AU2096901A (en) 2001-06-25
PL356172A1 (en) 2004-06-14
EP1237876A1 (en) 2002-09-11
CA2394570A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
CO4700453A1 (es) N-(INDOL-2-CARBONIL)-beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO AGENTES ANTIDIABETICOS
AR054982A1 (es) Compuestos de piperidinilamino-tieno [2,3-d] pirimidina
CO5150219A1 (es) Inhibidores de metaloproteasa que contiene alquenilo y alque nilo que son efectivos en el tratamiento de condiciones ca- racterizadas por actividad excesiva de estas enzimas
CO4960658A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
DE60004637D1 (de) N2-phenylamidine derivate
EA200100228A1 (ru) Трипептидные ингибиторы вируса гепатита с
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
CO5170534A1 (es) Derivados de fenil propionamida como activadores de la glucoquinasa
NO941361D0 (no) 1H-indol-3-acetamid sPLA2-inhibitorer
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
MX9202142A (es) Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende.
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
YU18999A (sh) Supstituisani tricikli
CO5160250A1 (es) Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen
CO5261565A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
AR035317A1 (es) Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos
ES2110260T3 (es) Androstenonas.
CO5261594A1 (es) Inhibidores de myt1 cinasa
ES2065478T3 (es) 2-amino-1,2,3,4-tetrahidronaftalenos y 3-aminocromanos sustituidos en el anillo.
CO5261516A1 (es) Compuestos de n-(i-feniletil)-5-femil-imidazol-2-amina y composicion que los comprende
CO4970802A1 (es) Compuesto bencimidazol-5 sustituido con estabilidad mejorada
NO872832L (no) FremgangsmŸte for fremstilling av terapeutisk aktive forbindelser.
AR026222A1 (es) Compuestos derivados de acido antranilico
KR890002134A (ko) 1,2-벤즈 이속 사졸 및 1,2-벤즈 이소 티아졸 유도체

Legal Events

Date Code Title Description
FA Application withdrawn